top of page
Federated AI Can’t Be Ignored - How Qubigen is Doing it Differently
At Qubigen, we do something fundamentally different: we build AI Engines for drug design using our secure Federated AI Drug Design platform (FedAIDD). The platform allows our clients to generate truly novel compounds, without their data ever leaving its server. Qubigen’s FedAIDD can also predict reaction pathways and optimize for desired ADME-T properties, ultimately saving on med-chem costs. Our mission is to unlock the full potential of pharmaceutical data without compromi
Nov 18, 20255 min read
Qubigen to Present at WEHI Divisional Seminar Program on 20 Nov 2025
Qubigen is pleased to announce that its CEO, Dr Jonathan Hall, and its Chief Information Officer, A/Prof Dr Jun Zeng, will be presenting at the Walter and Eliza Hall Institute of Medical Research (WEHI) Divisional Seminar Program . Hosted by Professor Guillaume Lessene, the seminar will explain how Qubigen’s proprietary Federated AI Platform (FedAIDD) is enabling a new paradigm in collaborative drug design. Date Thursday, 20 November 2025 Time 10:45 to 11:45 AM Location WEH
Nov 14, 20252 min read
Qubigen and US-Based Rio Pharmaceuticals Partner for AI-Enhanced Drug Design in Neurological Disease
Qubigen Pty Ltd is pleased to announce that it has entered into an agreement with Rio Pharmaceuticals , Inc., a San Francisco-based biotechnology company focused on developing imaging tracers for the diagnosis and staging of neurological disease. This agreement marks Rio’s first expansion into therapeutics, launching a multi-stage development program with Qubigen to develop novel small molecule therapeutics targeting a critical pathway in neurological diseases. Combining AI
Oct 23, 20252 min read
bottom of page